Navigation Links
Synthetic DNA Deemed Patentable by US Supreme Court, Gene Synthesis and Codon Optimization Provide Potential Pathway to Patentability
Date:6/20/2013

To preserve clients' intellectual property rights, GenScript does not claim any rights to specialized synthetic or OptimumGeneTM codon optimized genes. Custom project details are kept strictly confidential; all intellectual property rights belong to the client.

It may be too soon to speculate on the court ruling's effect on DNA sequences' future patentability. However, as the pace of molecular biology research quickens, the use of synthetic DNA will inevitably become a mainstay in every lab. GenScript offers gene synthesis and codon optimization solutions for the present and future of gene patent law and remains committed to supporting innovation.

*GenScript is not a legal practitioner and the content above is in no way intended to provide legal advice for patent prosecution, litigation or any associated legal matters thereof.


'/>"/>
SOURCE GenScript USA Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. "Sitting Ducks" No Longer: Advance Flu Warning Permits Creation of Replikins Custom Synthetic Flu Vaccine in Animals
2. Synthetic Biology: Emerging Global Markets
3. Synthetic Genomics Inc. Hires Industry Leader George E. Stagnitti to Head Food and Nutritional Products Development Program
4. New England Biolabs Signs Agreement with Synthetic Genomics Inc. to Launch Gibson Assembly™ Master Mix for Molecular and Synthetic Biology Applications
5. Startling results in synthetic chemistry presented in Nature Chemistry
6. Adeona Becomes Synthetic Biologics, Inc.
7. Synthetic Biologics to Present at ROTH Annual Growth Stock Conference
8. Synthetic Biologics Announces Completion of Enrollment in 164 Patient Clinical Trial of Oral Trimesta™ for Multiple Sclerosis
9. Synthetic Biologics Appoints Jeffrey J. Kraws as Independent Chairman
10. Synthetic Genomics Inc. Purchases 81 Acre Site in South California Desert for Scale up and Testing of Innovative Algae Strains
11. Discovered Evolution of Genomic Sequences -- from Ocean Archaea to Brain Cancer -- Leads to New Synthetic Replikin Vaccines for Infectious Diseases and Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... 2015 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS ... an optimized Erk inhibitor molecule for development, thus ... a new class of potential cancer therapies. ... target for therapeutic intervention in cancer. Recently approved ... for B-Raf and Mek inhibitors. Erk inhibitors may ...
(Date:7/29/2015)... ... 29, 2015 , ... Available in select spas and ... nighttime-specific product that targets fat cells for extreme contouring action. During sleep key ... cells, inhibiting the formation of new fat. Upon waking CHRONODIET breaks down fat ...
(Date:7/29/2015)... ... July 29, 2015 , ... ... making good progress in evaluating the full range of capabilities of its unique ... tissue stem cells perform the day-to-day renewal and repair of normal tissues and ...
(Date:7/28/2015)... ... July 29, 2015 , ... Strong Animals™ announced today that research conducted ... and presented at the ADSA-ASAS Joint Annual Meeting held July 12-16 in Orlando, FL ... and increased milk fat content. Also, feed containing Stay Strong™ for Dairy Cows took ...
Breaking Biology Technology:Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 2Aeterna Zentaris Announces Optimized Erk Inhibitor Compounds For Further Development 3Phytocéane introduces CHRONO NIGHT Express Contouring Bi-Gel 2Phytocéane introduces CHRONO NIGHT Express Contouring Bi-Gel 3Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 2Asymmetrex Plans to Report Results From Adult Stem Cell Technology Development Milestone Studies At End of Summer 3Asymmetrex Plans to Report Results From Adult Stem Cel